Papillary thyroid cancer: Time course of recurrences during postsurgery surveillance

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 636-642

  Durante, Cosimo ^a   Montesano, Teresa ^a   Torlontano, Massimo ^b   Attard, Marco ^c   Monzani, Fabio ^d   Tumino, Salvatore ^e   Costante, Giuseppe ^f   Meringolo, Domenico ^g   Bruno, Rocco ^h   Trulli, Fabiana ^a   Massa, Michela ^b   Maniglia, Adele ^c   Rosaria D'Apollo, ^a   Giacomelli, Laura ^a   Ronga, Giuseppe ^a   Filetti, Sebastiano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^g Ospedale di Bentivoglio   (Italy)

^h Tinchi Pisticci Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873686463     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3401     Document Type: Article

References (21)

1. American Thyroid Association (ATA) Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Task Force. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803.
3. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
4. DeGroot LJ. Long-term impact of initial and surgical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:499-500.
5. Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 2004;14:1056-1060.
6. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
7. Hall SF, Walker H, Siemens R, Schneeberg A. Increasing detection and increasing incidence in thyroid cancer. World J Surg. 2009;33: 2567-2571.
8. Durante C, Attard M, Torlontano M, et al. Papillary Thyroid Cancer Study Group. Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab. 2010;95:4882-4888.
9. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341-1349.
10. Castagna MG, Maino F, Cipri C, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165:441-446.
11. Leboulleux S, Girard E, Rose M, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92: 3590-3594.
12. Arturi F, Russo D, Giuffrida D, et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab. 1997;82:1638-1641.
13. Baudin E, Do Cao C, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003;88:1107-1111.
14. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004; 89:3402-3407.
15. Brassard M, Borget I, Edet-Sanson A, et al. THYRDIAG Working Group. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab. 2011;96:1352-1359.
16. Torlontano M, Crocetti U, D'Aloiso L, et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol. 2003;148:19-24.
17. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668-3673.
18. Torlontano M, Crocetti U, Augello G, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab. 2006; 91:60-63.
19. Schlumberger M, Hitzel A, Toubert ME, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab. 2007;92: 2487-2495.
20. Durante C, Montesano T, Attard M, et al, on behalf of the PTC Study Group. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J Clin Endocrinol Metab 2012;97:2748-2753.
21. Padovani RP, Robenshtok E, Brokhin M, Tuttle RM. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid. 2012;22:778-783.